- Home
- / MiNK Therapeutics
MiNK Therapeutics
Stock Price
$0.7
2024-10-29
Market Capitalization
$28.9 M
2024-10-29
MiNK Therapeutics Summary
Company Summary
- Overview
- MiNK Therapeutics (formerly AgenTus Biosciences, AgenTus Therapeutics) is a biopharmaceutical company that develops allogeneic iNKT cell therapies to treat cancer and immune-mediated diseases. Its products candidates include AGENT-797 for the treatment of multiple myeloma, a CAR-iNKT program targeting BCMA, and a tumor-stromal targeting CAR-iNKT program.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- New York, NY, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Garo Armen, Executive Chairman
Brian Corvese, Director
LocationsView all
2 locations detected
New York, NY HQ
United States
149 Fifth Avenue, Suite 500
Cambridge, England
United Kingdom
315 Cambridge Science Park Milton Rd
MiNK Therapeutics Financials
Summary Financials
- Net income (FY, 2024)
- ($10.8M)
- Cash (FY, 2024)
- $4.6M
- EBIT (FY, 2024)
- ($11.3M)
- Enterprise value
- $29.3M